References
- Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. Journal of Experimental Medicine 1992; 175: 323–329
- Barr RM, Walker SL, Tsang W, Harrison GJ, Ettehadi MW, Graves MW, Young AR. Suppressed alloantigen presentation, increased TNF-α, IL-1, IL-1Ra, IL-10, and modulation of TNF-R1 in UV-irradiated human skin. Journal of Investigative Dermatology 1999; 112: 692–698
- Brockhaus M, Schoenfeld H-J, Schlaeger E-J, Hunziker W, Lessauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proceedings of the National Academy of Sciences USA 1990; 87: 3127–3131
- Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 35: 1842–1847
- Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp DR. Elevated tumor necrosis factor alpha (TNF-α) biological activity in psoriatic skin lesions. Clinical & Experimental Immunology 1994; 96: 146–151
- Fredriksson T, Petersson V. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238–244
- Griffiths CEM, Boffa MJ, Gallatin WM, Martin S. Elevated levels of circulating intercellular adhesion molecule-3 (cICAM-3) in psoriasis. Acta Dermato-Venereologica (Stockholm) 1996; 76: 2–5
- Henseler T, Chrisophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. Journal of the American Academy of Dermatology 1985; 13: 450–456
- Hönigsmann H. Phototherapy for psoriasis. Clinical and Experimental Dermatology 2001; 26: 343–350
- Kirby B, Boffa MJ, Nayak N, Gallatin WM, Martin S, Griffiths CEM. The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumour necrosis factor-receptor 1 in psoriasis. British Journal of Dermatology 2001; 145: 1027–1028
- Köck A, Schwarz T, Kirnbauer R, Urbanski A, Perry P, Ansel JC, Luger TA. Human kernatinocytes are a source for tumor necrosis factor. Evidence for synthesis and release upon stimulation by endotoxin or ultraviolet light. Journal of Experimental Medicine 1990; 172: 1609–1614
- Kristensen M, Chu CQ, Eedy DJ, Feldman M, Brennan FM, Breathnach SM. Localization of tumor necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptor. Clinical and Experimental Immunology 1993; 94: 354–362
- Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000; 356: 1627–1632
- Naldi L, Griffiths CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. British Journal of Dermatology 2005; 152: 597–615
- Neuner P, Charvat B, Knobler R, Kirnbauer R, Schwarz A, Luger TA. Cytokine release by peripheral blood mononuclear cells is affected by 8-methoxypsoralen plus UV-A. Photochemistry and Photobiology 1994; 59: 182–188
- Olaniran AK, Baker BS, Paige DG, Garioch JJ, Powels AV, Fry L. Cytokine expression in psoriatic skin lesions during PUVA therapy. Archives of Dermatological Research 1996; 288: 421–425
- Piskin G, Tursen U, Sylva-Steenland RMR, Bos JD, Teunissen MBM. Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of INF-γ inducers – IL-1, IL-18 and IL-23. Experimental Dermatology 2004; 13: 764–772
- Schwarz T, Luger TA. New trends in photobiology: effect of UV irradiation on epidermal cell cytokine production. Journal of Photochemistry and Photobiology B 1989; 4: 1–13
- Serwin AB, Sokolowska M, Chodynicka B. Soluble tumor necrosis factor α receptor type 1 in psoriasis patients treated with narrowband ultraviolet B. Photodermatology, Photoimmunology and Photomedicine 2005; 21: 210–211
- Terajima S, Higaki M, Igarashi Y, Nogita T, Kawashima M. An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis. Archives of Dermatological Research 1998; 290: 246–252
- Trefzer U, Brockhaus M, Lötscher H, Parlow F, Budnik A, Grewe M, Christoph H, Kapp A, Schöpf E, Luger TA, Krutmann J. The 55-kD tumor necrosis factor receptor on human keratinocytes is regulated by tumor necrosis factor-alpha and by ultraviolet B radiation. Journal of Clinical Investigation 1993; 92: 462–470